Treatment of unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still the mainstay of treatment. However, following the 2016-2017 FDA approvals of the PD-L1 inhibitor Tecentriq (Roche/Genentech) and the PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for platinum-treated patients (i.e., second and later lines), immune checkpoint inhibitors are revolutionizing the treatment algorithm for this indication.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in January 2017
Key companies: Bristol-Myers Squibb, Eli Lilly, Roche/Genentech
Key drugs: Tecentriq, Javlor, gemcitabine